Imugene Limited is an ASX-listed clinical-stage biotechnology company developing immunotherapies to treat cancer. Its pipeline includes cancer vaccines, CAR-T cell therapies, and oncolytic virus treatments designed to activate the immune system against tumours. The company focuses on clinical trials to advance potential breakthrough oncology treatments and long-term therapeutic platforms.
Imugene Limited (ASX:IMU)
IMU
Lead Manager
Contact - Kirwan Mactaggart
0448 237 054
kirwan@liquidity.com.au
Offer Price
A$0.180
per share
Offer Size
A$20,000,000
Offer Details
Issue Price (Per Share)
A$0.180
Discount
-56.52%
Offer Size
A$20,000,000
Shares Available
111,100,000
A$20,000,000 Placement 110,100,000 New Securities Offer price - $0.18 per share
Discount
32.5% discount to the 30-day VWAP
Options
Every one (1) New Security under the Offer and SPP will receive one (1) free-attaching quoted option (“Attaching Options”). Attaching Options will each be exercisable at an exercise price of A$0.18 and have an expiry date of 30 April 2027.
Upon exercise of every one (1) Attaching Option, each holder will receive one (1) piggyback option, which is exercisable at an exercise price of A$0.30 each and has an expiry date of 30 April 2029 (“Piggyback Options”).
Tranches
- Tranche 1 to raise A$6.4 million (before costs) utilising the Company’s available placement capacity under ASX Listing Rules 7.1 and 7.1A; and
- Tranche 2 to raise up to A$5.6 million (before costs) subject to shareholder approval to be sought at an EGM (defined below) expected to be held in mid April; and
Company Overview
Imugene Limited is an Australian clinical-stage biotechnology company focused on developing immuno-oncology therapies that harness the body’s immune system to identify and destroy cancer cells. The company is listed on the Australian Securities Exchange (ASX: IMU) and is headquartered in Sydney.
Imugene’s strategy is to build a diverse pipeline of cancer treatments across multiple immunotherapy technologies. Its programs include B-cell cancer vaccines, CAR-T cell therapies, and oncolytic virus platforms designed to improve immune recognition of tumours and enhance responses to existing checkpoint inhibitors.
Key assets in the pipeline include the CF33 oncolytic virus platform, which is being developed to selectively infect and destroy tumour cells while stimulating immune responses, and HER-Vaxx and PD1-Vaxx, therapeutic vaccines targeting specific cancer proteins. The company also acquired azer-cel, an off-the-shelf CAR-T therapy targeting CD19-positive blood cancers.
As a clinical-stage biotech, Imugene currently generates limited commercial revenue and is primarily funded through capital markets. Its value proposition is driven by clinical trial progress, strategic partnerships, and potential future approvals of its oncology therapies.
Use of Funds - Sources
Sources
Offer Proceeds
$20.0m
Total Sources
$30.6m
Cash at Hand as of 1 February 2026
$10.6m
Use of Funds - Uses
Uses
General Administrative
$11.0m
Wind Down of Legacy Programs
$3.5m
Offer Costs
$0.7m
Total Uses
$30.6m
Azer-cel
$15.4m
Disclaimer
This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of the Company. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.
Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in the Company.
